Compare GHG & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
Current Price
Current Price
| Metric | GHG | DCTH |
|---|---|---|
| Founded | 2004 | 1988 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.1M | 350.7M |
| IPO Year | 2018 | N/A |
| Metric | GHG | DCTH |
|---|---|---|
| Price | $1.76 | $10.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $22.60 |
| AVG Volume (30 Days) | 20.3K | ★ 682.8K |
| Earning Date | 01-02-2026 | 11-04-2025 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | 0.03 |
| Revenue | ★ $174,012,060.00 | $79,603,000.00 |
| Revenue This Year | $19.02 | $131.97 |
| Revenue Next Year | $8.26 | $38.84 |
| P/E Ratio | ★ $6.55 | $291.54 |
| Revenue Growth | N/A | ★ 251.54 |
| 52 Week Low | $1.66 | $8.12 |
| 52 Week High | $3.25 | $18.23 |
| Indicator | GHG | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 55.89 |
| Support Level | $1.66 | $9.84 |
| Resistance Level | $1.87 | $10.28 |
| Average True Range (ATR) | 0.08 | 0.45 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 28.26 | 57.50 |
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.